Charles Quick
Concepts (404)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endometrial Neoplasms | 18 | 2021 | 138 | 4.530 |
Why?
| Carcinoma in Situ | 7 | 2022 | 72 | 1.970 |
Why?
| Uterine Neoplasms | 10 | 2023 | 60 | 1.960 |
Why?
| Vulvar Neoplasms | 5 | 2022 | 52 | 1.900 |
Why?
| Carcinoma, Endometrioid | 6 | 2021 | 38 | 1.630 |
Why?
| Adenocarcinoma | 10 | 2024 | 397 | 1.590 |
Why?
| Carcinoma, Squamous Cell | 8 | 2019 | 318 | 1.470 |
Why?
| PAX2 Transcription Factor | 7 | 2015 | 22 | 1.460 |
Why?
| Uterine Cervical Neoplasms | 7 | 2024 | 276 | 1.200 |
Why?
| Ovarian Neoplasms | 10 | 2024 | 447 | 1.190 |
Why?
| Endometrial Hyperplasia | 4 | 2019 | 14 | 1.150 |
Why?
| Stromal Cells | 2 | 2016 | 72 | 1.030 |
Why?
| Sarcoma, Alveolar Soft Part | 1 | 2023 | 1 | 0.910 |
Why?
| Cannabidiol | 5 | 2024 | 38 | 0.890 |
Why?
| Female | 65 | 2024 | 26635 | 0.880 |
Why?
| Myometrium | 2 | 2013 | 14 | 0.860 |
Why?
| Endometrium | 6 | 2023 | 41 | 0.830 |
Why?
| Adenocarcinoma, Clear Cell | 6 | 2019 | 34 | 0.780 |
Why?
| Precancerous Conditions | 3 | 2019 | 83 | 0.760 |
Why?
| Aged, 80 and over | 20 | 2024 | 3154 | 0.730 |
Why?
| Cystadenocarcinoma, Serous | 4 | 2013 | 71 | 0.700 |
Why?
| Plant Extracts | 5 | 2024 | 171 | 0.690 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2017 | 203 | 0.660 |
Why?
| Humans | 68 | 2024 | 50208 | 0.640 |
Why?
| Middle Aged | 34 | 2024 | 12206 | 0.630 |
Why?
| Peripheral Nerves | 2 | 2015 | 49 | 0.630 |
Why?
| Aged | 29 | 2024 | 9405 | 0.600 |
Why?
| Mutation | 9 | 2024 | 1294 | 0.600 |
Why?
| Placenta | 6 | 2021 | 132 | 0.580 |
Why?
| Cervix Uteri | 2 | 2017 | 49 | 0.570 |
Why?
| Epithelial-Mesenchymal Transition | 2 | 2016 | 48 | 0.570 |
Why?
| Adult | 31 | 2024 | 13324 | 0.560 |
Why?
| Immunohistochemistry | 15 | 2020 | 978 | 0.550 |
Why?
| Adenosarcoma | 1 | 2016 | 3 | 0.550 |
Why?
| Cannabis | 5 | 2024 | 145 | 0.550 |
Why?
| Polyps | 1 | 2016 | 21 | 0.540 |
Why?
| Uterine Cervical Dysplasia | 1 | 2016 | 49 | 0.530 |
Why?
| Neoplasm Staging | 9 | 2024 | 738 | 0.510 |
Why?
| Lymphatic Metastasis | 6 | 2019 | 227 | 0.510 |
Why?
| Fibroma | 1 | 2015 | 39 | 0.510 |
Why?
| Fallopian Tubes | 2 | 2012 | 22 | 0.500 |
Why?
| Tumor Microenvironment | 4 | 2021 | 233 | 0.500 |
Why?
| Prognosis | 11 | 2024 | 1954 | 0.460 |
Why?
| Neoplasm Invasiveness | 6 | 2019 | 266 | 0.450 |
Why?
| Pelvic Neoplasms | 1 | 2011 | 14 | 0.400 |
Why?
| Uterus | 3 | 2023 | 94 | 0.390 |
Why?
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 78 | 0.390 |
Why?
| Ejaculatory Ducts | 1 | 2010 | 3 | 0.360 |
Why?
| Seminal Vesicles | 1 | 2010 | 13 | 0.360 |
Why?
| Neoplasm Recurrence, Local | 4 | 2015 | 613 | 0.360 |
Why?
| Spectrum Analysis, Raman | 2 | 2021 | 58 | 0.350 |
Why?
| Prostate | 1 | 2010 | 117 | 0.340 |
Why?
| Bromcresol Purple | 1 | 2009 | 3 | 0.330 |
Why?
| Electrophoresis, Capillary | 1 | 2009 | 11 | 0.330 |
Why?
| Serum Albumin | 1 | 2009 | 58 | 0.320 |
Why?
| Mice, Inbred C57BL | 6 | 2024 | 1819 | 0.320 |
Why?
| Human papillomavirus 16 | 2 | 2021 | 44 | 0.320 |
Why?
| Methionine | 2 | 2020 | 135 | 0.310 |
Why?
| beta Catenin | 2 | 2021 | 102 | 0.310 |
Why?
| Disease Progression | 4 | 2020 | 831 | 0.310 |
Why?
| Mice | 15 | 2024 | 5759 | 0.300 |
Why?
| Diabetes Mellitus | 2 | 2023 | 286 | 0.300 |
Why?
| Papillomavirus Infections | 2 | 2022 | 155 | 0.300 |
Why?
| Papillomavirus Vaccines | 2 | 2021 | 61 | 0.290 |
Why?
| Genital Neoplasms, Female | 2 | 2018 | 41 | 0.290 |
Why?
| Anus Neoplasms | 2 | 2018 | 24 | 0.290 |
Why?
| Metaplasia | 2 | 2019 | 16 | 0.290 |
Why?
| Cell Proliferation | 4 | 2021 | 1013 | 0.280 |
Why?
| Antigens, CD | 2 | 2019 | 221 | 0.280 |
Why?
| Diagnosis, Differential | 8 | 2020 | 1043 | 0.280 |
Why?
| Prostatic Neoplasms | 1 | 2010 | 394 | 0.270 |
Why?
| Colitis | 2 | 2020 | 51 | 0.270 |
Why?
| Polyethylene Glycols | 2 | 2017 | 93 | 0.260 |
Why?
| Melanoma | 2 | 2020 | 290 | 0.260 |
Why?
| Neoplasm Grading | 5 | 2021 | 123 | 0.260 |
Why?
| Hypertension | 2 | 2021 | 537 | 0.260 |
Why?
| Chi-Square Distribution | 2 | 2016 | 278 | 0.250 |
Why?
| Gold | 2 | 2017 | 136 | 0.250 |
Why?
| Proteomics | 3 | 2017 | 330 | 0.240 |
Why?
| Nanoparticles | 2 | 2017 | 152 | 0.240 |
Why?
| Young Adult | 7 | 2024 | 3981 | 0.240 |
Why?
| Aspartic Acid Endopeptidases | 2 | 2015 | 16 | 0.240 |
Why?
| Racemases and Epimerases | 2 | 2015 | 15 | 0.240 |
Why?
| Retrospective Studies | 11 | 2020 | 6134 | 0.240 |
Why?
| Sex Cord-Gonadal Stromal Tumors | 1 | 2024 | 3 | 0.240 |
Why?
| Neuroendocrine Tumors | 1 | 2024 | 23 | 0.230 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2024 | 24 | 0.230 |
Why?
| Animals | 16 | 2024 | 13246 | 0.230 |
Why?
| Head and Neck Neoplasms | 2 | 2019 | 273 | 0.230 |
Why?
| DNA Mutational Analysis | 3 | 2024 | 176 | 0.230 |
Why?
| Kidney Neoplasms | 2 | 2018 | 176 | 0.220 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 41 | 0.220 |
Why?
| Homeodomain Proteins | 1 | 2024 | 80 | 0.220 |
Why?
| Chlamydia muridarum | 1 | 2024 | 41 | 0.220 |
Why?
| Lung Neoplasms | 2 | 2019 | 605 | 0.220 |
Why?
| Endometriosis | 1 | 2023 | 14 | 0.220 |
Why?
| Gynecology | 2 | 2020 | 49 | 0.210 |
Why?
| Chlamydia Infections | 1 | 2024 | 77 | 0.210 |
Why?
| Adenocarcinoma, Sebaceous | 1 | 2022 | 7 | 0.210 |
Why?
| Sebaceous Gland Neoplasms | 1 | 2022 | 16 | 0.210 |
Why?
| Observer Variation | 3 | 2017 | 129 | 0.210 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2024 | 164 | 0.210 |
Why?
| Fallopian Tube Neoplasms | 2 | 2012 | 14 | 0.200 |
Why?
| Immunotherapy | 2 | 2021 | 240 | 0.200 |
Why?
| Gestational Trophoblastic Disease | 2 | 2012 | 2 | 0.200 |
Why?
| Genotype | 2 | 2021 | 534 | 0.200 |
Why?
| CTLA-4 Antigen | 1 | 2021 | 25 | 0.200 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2021 | 22 | 0.190 |
Why?
| Oncogene Fusion | 1 | 2021 | 4 | 0.190 |
Why?
| PTEN Phosphohydrolase | 3 | 2020 | 55 | 0.190 |
Why?
| Estrogens | 2 | 2023 | 228 | 0.190 |
Why?
| Leiomyosarcoma | 1 | 2021 | 23 | 0.190 |
Why?
| Transcription Factors | 3 | 2020 | 564 | 0.190 |
Why?
| Diabetes, Gestational | 1 | 2021 | 52 | 0.190 |
Why?
| Cancer Vaccines | 1 | 2021 | 78 | 0.190 |
Why?
| Carcinosarcoma | 2 | 2017 | 18 | 0.180 |
Why?
| Infant, Small for Gestational Age | 1 | 2020 | 34 | 0.180 |
Why?
| Carcinoma, Papillary | 1 | 2020 | 49 | 0.180 |
Why?
| Neoplasms, Experimental | 1 | 2020 | 114 | 0.180 |
Why?
| Carcinoma, Transitional Cell | 1 | 2020 | 52 | 0.180 |
Why?
| Colonic Neoplasms | 1 | 2021 | 159 | 0.170 |
Why?
| Pregnancy in Diabetics | 1 | 2020 | 29 | 0.170 |
Why?
| Dermatology | 1 | 2020 | 49 | 0.170 |
Why?
| Carcinoma, Signet Ring Cell | 1 | 2019 | 14 | 0.170 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2019 | 22 | 0.170 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 10 | 0.170 |
Why?
| Radiotherapy | 1 | 2020 | 127 | 0.170 |
Why?
| Placenta Diseases | 1 | 2019 | 14 | 0.170 |
Why?
| Carcinoma, Renal Cell | 2 | 2018 | 105 | 0.170 |
Why?
| Skin Diseases | 1 | 2020 | 111 | 0.170 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.170 |
Why?
| Premature Birth | 1 | 2021 | 147 | 0.170 |
Why?
| Odds Ratio | 3 | 2015 | 546 | 0.170 |
Why?
| Hodgkin Disease | 1 | 2019 | 44 | 0.170 |
Why?
| DNA Polymerase II | 1 | 2019 | 9 | 0.170 |
Why?
| DNA Mismatch Repair | 1 | 2019 | 16 | 0.170 |
Why?
| Melanoma, Experimental | 1 | 2019 | 45 | 0.170 |
Why?
| Inflammation | 2 | 2020 | 604 | 0.170 |
Why?
| Fetal Diseases | 1 | 2019 | 61 | 0.170 |
Why?
| T-Lymphocytes | 1 | 2021 | 339 | 0.160 |
Why?
| Sarcoma | 1 | 2020 | 67 | 0.160 |
Why?
| Monocytes | 1 | 2019 | 131 | 0.160 |
Why?
| Urinary Bladder Neoplasms | 1 | 2020 | 156 | 0.160 |
Why?
| Reproducibility of Results | 4 | 2017 | 1185 | 0.160 |
Why?
| Metformin | 1 | 2020 | 65 | 0.160 |
Why?
| Pregnancy | 7 | 2021 | 2604 | 0.160 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.160 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 128 | 0.160 |
Why?
| Logistic Models | 3 | 2015 | 889 | 0.160 |
Why?
| Nuclear Proteins | 1 | 2020 | 243 | 0.150 |
Why?
| Hypoglycemic Agents | 1 | 2020 | 168 | 0.150 |
Why?
| Radiation Tolerance | 1 | 2019 | 85 | 0.150 |
Why?
| Disease Models, Animal | 6 | 2020 | 1458 | 0.150 |
Why?
| Neural Cell Adhesion Molecule L1 | 1 | 2017 | 1 | 0.150 |
Why?
| Rhabdomyosarcoma | 1 | 2018 | 13 | 0.150 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 39 | 0.150 |
Why?
| DNA Helicases | 1 | 2020 | 144 | 0.150 |
Why?
| Intestinal Mucosa | 2 | 2020 | 215 | 0.150 |
Why?
| Pathology, Molecular | 1 | 2017 | 22 | 0.150 |
Why?
| Hepatocytes | 1 | 2019 | 182 | 0.150 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 66 | 0.150 |
Why?
| Biopsy | 5 | 2020 | 590 | 0.150 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2019 | 388 | 0.150 |
Why?
| Liver | 3 | 2024 | 1116 | 0.150 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 55 | 0.150 |
Why?
| Pregnancy Complications | 1 | 2021 | 382 | 0.140 |
Why?
| Osteosarcoma | 1 | 2017 | 47 | 0.140 |
Why?
| Neoplastic Cells, Circulating | 1 | 2017 | 74 | 0.140 |
Why?
| Vimentin | 1 | 2016 | 32 | 0.140 |
Why?
| Gene Expression Profiling | 2 | 2019 | 1037 | 0.140 |
Why?
| Papillomaviridae | 1 | 2017 | 102 | 0.140 |
Why?
| Time Factors | 3 | 2021 | 2922 | 0.140 |
Why?
| Acetaminophen | 1 | 2019 | 283 | 0.140 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 411 | 0.130 |
Why?
| DNA-Binding Proteins | 2 | 2016 | 428 | 0.130 |
Why?
| Cadherins | 1 | 2016 | 68 | 0.130 |
Why?
| Viral Load | 1 | 2016 | 77 | 0.130 |
Why?
| Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 5 | 0.130 |
Why?
| Skin Neoplasms | 1 | 2020 | 492 | 0.130 |
Why?
| Neoplasms, Muscle Tissue | 1 | 2015 | 12 | 0.120 |
Why?
| Malate Dehydrogenase | 1 | 2014 | 9 | 0.120 |
Why?
| Classification | 1 | 2015 | 14 | 0.120 |
Why?
| Colposcopy | 1 | 2015 | 18 | 0.120 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 18 | 0.120 |
Why?
| Lipogenesis | 1 | 2014 | 29 | 0.120 |
Why?
| World Health Organization | 1 | 2015 | 48 | 0.120 |
Why?
| Flow Cytometry | 1 | 2017 | 476 | 0.120 |
Why?
| Cytosol | 1 | 2014 | 82 | 0.120 |
Why?
| Mice, Inbred BALB C | 3 | 2021 | 305 | 0.120 |
Why?
| Adolescent | 4 | 2024 | 6390 | 0.120 |
Why?
| Neoplasm, Residual | 1 | 2015 | 165 | 0.120 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2015 | 121 | 0.120 |
Why?
| Histones | 1 | 2016 | 313 | 0.120 |
Why?
| Obesity | 1 | 2022 | 1108 | 0.120 |
Why?
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 170 | 0.120 |
Why?
| Multiple Myeloma | 1 | 2009 | 2954 | 0.120 |
Why?
| Antineoplastic Agents | 2 | 2021 | 1186 | 0.110 |
Why?
| Gastrointestinal Tract | 1 | 2014 | 101 | 0.110 |
Why?
| Male | 10 | 2024 | 25399 | 0.110 |
Why?
| Intestines | 1 | 2014 | 168 | 0.110 |
Why?
| Oncogenes | 1 | 2013 | 57 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 253 | 0.110 |
Why?
| Cell Line, Tumor | 4 | 2020 | 1416 | 0.110 |
Why?
| Clusterin | 1 | 2012 | 6 | 0.110 |
Why?
| Predictive Value of Tests | 4 | 2018 | 905 | 0.110 |
Why?
| Membrane Proteins | 1 | 2015 | 353 | 0.110 |
Why?
| Risk Factors | 3 | 2015 | 3629 | 0.110 |
Why?
| Pancreatic Neoplasms | 1 | 2015 | 208 | 0.110 |
Why?
| Histocytochemistry | 1 | 2012 | 47 | 0.100 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 22 | 0.100 |
Why?
| Strongyloidiasis | 1 | 2012 | 10 | 0.100 |
Why?
| Follow-Up Studies | 2 | 2016 | 2190 | 0.100 |
Why?
| Treatment Outcome | 3 | 2021 | 5155 | 0.100 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 35 | 0.100 |
Why?
| Prednisone | 1 | 2012 | 101 | 0.100 |
Why?
| Tissue Inhibitor of Metalloproteinases | 1 | 2011 | 11 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 202 | 0.100 |
Why?
| Teratoma | 1 | 2011 | 26 | 0.100 |
Why?
| Matrix Metalloproteinases | 1 | 2011 | 48 | 0.090 |
Why?
| Sensitivity and Specificity | 3 | 2020 | 863 | 0.090 |
Why?
| Adenoma, Oxyphilic | 1 | 2010 | 11 | 0.090 |
Why?
| Image Processing, Computer-Assisted | 1 | 2012 | 246 | 0.090 |
Why?
| Phenotype | 3 | 2019 | 733 | 0.090 |
Why?
| Tissue Array Analysis | 3 | 2015 | 45 | 0.090 |
Why?
| Glucocorticoids | 1 | 2012 | 226 | 0.090 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 468 | 0.080 |
Why?
| Epigenesis, Genetic | 1 | 2012 | 378 | 0.080 |
Why?
| Pregnancy Outcome | 2 | 2021 | 237 | 0.080 |
Why?
| Pilot Projects | 2 | 2023 | 697 | 0.080 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 140 | 0.080 |
Why?
| Infant, Newborn | 3 | 2021 | 2766 | 0.080 |
Why?
| Telemedicine | 1 | 2015 | 449 | 0.080 |
Why?
| Necrosis | 2 | 2024 | 178 | 0.080 |
Why?
| Cell Differentiation | 2 | 2024 | 650 | 0.080 |
Why?
| Hysterectomy | 2 | 2021 | 88 | 0.080 |
Why?
| Cell Nucleus | 2 | 2021 | 187 | 0.080 |
Why?
| Societies, Medical | 2 | 2019 | 177 | 0.070 |
Why?
| Host-Pathogen Interactions | 2 | 2021 | 135 | 0.070 |
Why?
| Neoplasms | 1 | 2017 | 1249 | 0.070 |
Why?
| Gene Expression Regulation | 3 | 2023 | 979 | 0.070 |
Why?
| Consensus | 2 | 2020 | 150 | 0.070 |
Why?
| Ventricular Pressure | 1 | 2006 | 16 | 0.070 |
Why?
| Isoproterenol | 1 | 2006 | 56 | 0.070 |
Why?
| Terminology as Topic | 2 | 2018 | 62 | 0.070 |
Why?
| Kaplan-Meier Estimate | 2 | 2018 | 465 | 0.070 |
Why?
| Serum Response Factor | 1 | 2006 | 42 | 0.070 |
Why?
| Combined Modality Therapy | 2 | 2020 | 636 | 0.070 |
Why?
| Kidney | 1 | 2010 | 672 | 0.070 |
Why?
| Practice Guidelines as Topic | 2 | 2019 | 449 | 0.070 |
Why?
| Neoplasm Metastasis | 2 | 2018 | 236 | 0.060 |
Why?
| Cytokines | 2 | 2020 | 613 | 0.060 |
Why?
| Cells, Cultured | 2 | 2021 | 1581 | 0.060 |
Why?
| Proportional Hazards Models | 2 | 2017 | 410 | 0.060 |
Why?
| Chromatography, Liquid | 2 | 2016 | 225 | 0.060 |
Why?
| Bilirubin | 1 | 2024 | 40 | 0.060 |
Why?
| Tandem Mass Spectrometry | 2 | 2016 | 231 | 0.060 |
Why?
| Species Specificity | 1 | 2024 | 192 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 2 | 2019 | 1378 | 0.060 |
Why?
| Heart | 1 | 2006 | 331 | 0.060 |
Why?
| Steroids | 1 | 2024 | 57 | 0.060 |
Why?
| Th1 Cells | 1 | 2024 | 52 | 0.060 |
Why?
| Interleukin-10 | 1 | 2024 | 84 | 0.060 |
Why?
| Phylogeny | 1 | 2024 | 234 | 0.050 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 828 | 0.050 |
Why?
| Government Agencies | 1 | 2022 | 14 | 0.050 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 64 | 0.050 |
Why?
| Hemorrhage | 1 | 2024 | 197 | 0.050 |
Why?
| Choriocarcinoma | 2 | 2012 | 7 | 0.050 |
Why?
| Genes, T-Cell Receptor | 1 | 2021 | 5 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 11 | 0.050 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2021 | 25 | 0.050 |
Why?
| Parturition | 1 | 2021 | 51 | 0.050 |
Why?
| Phthalazines | 1 | 2021 | 20 | 0.050 |
Why?
| Remission Induction | 1 | 2021 | 207 | 0.050 |
Why?
| Quinazolines | 1 | 2021 | 33 | 0.050 |
Why?
| Lymphocyte Activation | 1 | 2021 | 172 | 0.050 |
Why?
| Vulva | 1 | 2020 | 17 | 0.050 |
Why?
| Taurine | 1 | 2020 | 15 | 0.050 |
Why?
| Research Report | 1 | 2020 | 16 | 0.050 |
Why?
| Metabolic Networks and Pathways | 1 | 2021 | 89 | 0.050 |
Why?
| Herb-Drug Interactions | 1 | 2020 | 31 | 0.050 |
Why?
| Mucin-2 | 1 | 2020 | 7 | 0.050 |
Why?
| Toxicity Tests | 1 | 2020 | 54 | 0.050 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 95 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 121 | 0.040 |
Why?
| Risk | 1 | 2021 | 324 | 0.040 |
Why?
| Piperazines | 1 | 2021 | 118 | 0.040 |
Why?
| Chemokines | 1 | 2020 | 78 | 0.040 |
Why?
| United States | 3 | 2016 | 4874 | 0.040 |
Why?
| Birth Weight | 1 | 2020 | 120 | 0.040 |
Why?
| Preoperative Period | 1 | 2020 | 47 | 0.040 |
Why?
| Chorionic Villi | 1 | 2019 | 3 | 0.040 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2020 | 36 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 595 | 0.040 |
Why?
| Colon | 1 | 2020 | 94 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 39 | 0.040 |
Why?
| Pyrimidines | 1 | 2021 | 193 | 0.040 |
Why?
| Chest Pain | 1 | 2019 | 55 | 0.040 |
Why?
| Receptors, Progesterone | 1 | 2020 | 64 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2014 | 550 | 0.040 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2019 | 32 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 63 | 0.040 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2020 | 195 | 0.040 |
Why?
| Glutamine | 1 | 2020 | 171 | 0.040 |
Why?
| Dyspnea | 1 | 2019 | 75 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2020 | 89 | 0.040 |
Why?
| Liver Function Tests | 1 | 2019 | 47 | 0.040 |
Why?
| Fatal Outcome | 1 | 2019 | 195 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 161 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 151 | 0.040 |
Why?
| Gestational Age | 1 | 2020 | 418 | 0.040 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 153 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 254 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2019 | 212 | 0.040 |
Why?
| Mullerian Ducts | 1 | 2018 | 4 | 0.040 |
Why?
| Nephrectomy | 1 | 2018 | 83 | 0.040 |
Why?
| Wolffian Ducts | 1 | 2018 | 2 | 0.040 |
Why?
| Mutation Rate | 1 | 2018 | 36 | 0.040 |
Why?
| Lymph Node Excision | 1 | 2019 | 137 | 0.040 |
Why?
| Cell Lineage | 1 | 2018 | 84 | 0.040 |
Why?
| Ultrasonography, Prenatal | 1 | 2019 | 186 | 0.040 |
Why?
| Mixed Tumor, Mullerian | 1 | 2017 | 3 | 0.040 |
Why?
| DNA Copy Number Variations | 1 | 2018 | 110 | 0.040 |
Why?
| Skin | 1 | 2020 | 415 | 0.040 |
Why?
| Anal Canal | 1 | 2017 | 21 | 0.040 |
Why?
| Macrophages | 1 | 2019 | 363 | 0.040 |
Why?
| Dietary Supplements | 1 | 2020 | 434 | 0.040 |
Why?
| Child | 2 | 2024 | 6851 | 0.030 |
Why?
| Matrix Attachment Region Binding Proteins | 1 | 2017 | 35 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2017 | 454 | 0.030 |
Why?
| Lymph Nodes | 1 | 2019 | 263 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 320 | 0.030 |
Why?
| Telomerase | 1 | 2016 | 27 | 0.030 |
Why?
| Vaccines, Subunit | 1 | 2016 | 15 | 0.030 |
Why?
| Ontario | 1 | 2016 | 49 | 0.030 |
Why?
| Diet | 1 | 2020 | 557 | 0.030 |
Why?
| Mesonephros | 1 | 2016 | 1 | 0.030 |
Why?
| Signal Transduction | 1 | 2023 | 1622 | 0.030 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 8 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2016 | 86 | 0.030 |
Why?
| Extracellular Fluid | 1 | 2015 | 14 | 0.030 |
Why?
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2016 | 115 | 0.030 |
Why?
| S100 Proteins | 1 | 2015 | 34 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 63 | 0.030 |
Why?
| Cell Count | 1 | 2015 | 149 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2015 | 82 | 0.030 |
Why?
| Pressure | 1 | 2015 | 106 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2015 | 143 | 0.030 |
Why?
| Blood Vessels | 1 | 2015 | 71 | 0.030 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 51 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 509 | 0.030 |
Why?
| Random Allocation | 1 | 2015 | 282 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 145 | 0.030 |
Why?
| Prospective Studies | 1 | 2020 | 2379 | 0.030 |
Why?
| Radiotherapy Dosage | 1 | 2015 | 246 | 0.030 |
Why?
| Proteome | 1 | 2016 | 173 | 0.030 |
Why?
| Apoptosis | 1 | 2020 | 1112 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| Likelihood Functions | 1 | 2014 | 54 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2015 | 259 | 0.030 |
Why?
| Vaccination | 1 | 2016 | 271 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 581 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 747 | 0.030 |
Why?
| Genes, erbB-1 | 1 | 2013 | 8 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2014 | 175 | 0.030 |
Why?
| Gene Frequency | 1 | 2013 | 94 | 0.030 |
Why?
| Adiposity | 1 | 2014 | 133 | 0.030 |
Why?
| SEER Program | 1 | 2013 | 92 | 0.030 |
Why?
| Communication | 1 | 2015 | 246 | 0.030 |
Why?
| Mesentery | 1 | 2012 | 32 | 0.030 |
Why?
| Rural Health Services | 1 | 2015 | 164 | 0.030 |
Why?
| Research Design | 1 | 2015 | 342 | 0.030 |
Why?
| Insulin Resistance | 1 | 2014 | 262 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 5 | 0.030 |
Why?
| Pregnancy Proteins | 1 | 2012 | 5 | 0.030 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 42 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 6 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2015 | 579 | 0.030 |
Why?
| Angiopoietin-2 | 1 | 2012 | 15 | 0.030 |
Why?
| Angiopoietin-1 | 1 | 2012 | 16 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2014 | 220 | 0.030 |
Why?
| Ovary | 1 | 2012 | 115 | 0.030 |
Why?
| Ivermectin | 1 | 2012 | 9 | 0.030 |
Why?
| Antiparasitic Agents | 1 | 2012 | 10 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 32 | 0.030 |
Why?
| Infant | 1 | 2020 | 3563 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 618 | 0.020 |
Why?
| Hydatidiform Mole | 1 | 2011 | 2 | 0.020 |
Why?
| RNA, Messenger | 1 | 2014 | 1108 | 0.020 |
Why?
| Crohn Disease | 1 | 2012 | 90 | 0.020 |
Why?
| Isoenzymes | 1 | 2011 | 169 | 0.020 |
Why?
| Interleukin-6 | 1 | 2012 | 265 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2012 | 475 | 0.020 |
Why?
| Gene Expression | 1 | 2012 | 609 | 0.020 |
Why?
| Risk Assessment | 1 | 2015 | 1262 | 0.020 |
Why?
| Radiography | 1 | 2011 | 491 | 0.020 |
Why?
| Cell Line | 1 | 2012 | 1021 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1422 | 0.020 |
Why?
| DNA Methylation | 1 | 2012 | 550 | 0.020 |
Why?
| Rats | 1 | 2014 | 3299 | 0.020 |
Why?
| Blotting, Western | 1 | 2006 | 601 | 0.020 |
Why?
| Myocardium | 1 | 2006 | 438 | 0.010 |
Why?
| Age Factors | 1 | 2006 | 1092 | 0.010 |
Why?
|
|
Quick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|